JP2019529421A - ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 - Google Patents

ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 Download PDF

Info

Publication number
JP2019529421A
JP2019529421A JP2019514787A JP2019514787A JP2019529421A JP 2019529421 A JP2019529421 A JP 2019529421A JP 2019514787 A JP2019514787 A JP 2019514787A JP 2019514787 A JP2019514787 A JP 2019514787A JP 2019529421 A JP2019529421 A JP 2019529421A
Authority
JP
Japan
Prior art keywords
pyrrolo
methyl
fluoro
pyridin
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019514787A
Other languages
English (en)
Japanese (ja)
Inventor
カケーシャン サルバチオン
カケーシャン サルバチオン
エー．クレアモン デイビッド
エー．クレアモン デイビッド
トン チョンクオ
トン チョンクオ
ファン イー
ファン イー
チア ランチー
チア ランチー
ディー．ロテスタ スティーブン
ディー．ロテスタ スティーブン
ビー．シン スレッシュ
ビー．シン スレッシュ
ベンカトラマン シャンカー
ベンカトラマン シャンカー
ユアン チン
ユアン チン
チョン ヤーチュン
チョン ヤーチュン
チョアン リンハン
チョアン リンハン
Original Assignee
ヴァイティー ファーマシューティカルズ，エルエルシー
ヴァイティー ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァイティー ファーマシューティカルズ，エルエルシー, ヴァイティー ファーマシューティカルズ，エルエルシー filed Critical ヴァイティー ファーマシューティカルズ，エルエルシー
Publication of JP2019529421A publication Critical patent/JP2019529421A/ja
Priority to JP2022161777A priority Critical patent/JP2022189853A/ja
Priority to JP2024195965A priority patent/JP2025022910A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019514787A 2016-09-16 2017-09-15 ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 Withdrawn JP2019529421A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022161777A JP2022189853A (ja) 2016-09-16 2022-10-06 ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤
JP2024195965A JP2025022910A (ja) 2016-09-16 2024-11-08 ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395618P 2016-09-16 2016-09-16
US62/395,618 2016-09-16
PCT/US2017/051780 WO2018053267A1 (en) 2016-09-16 2017-09-15 Inhibitors of the menin-mll interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022161777A Division JP2022189853A (ja) 2016-09-16 2022-10-06 ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤

Publications (1)

Publication Number Publication Date
JP2019529421A true JP2019529421A (ja) 2019-10-17

Family

ID=59966892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019514787A Withdrawn JP2019529421A (ja) 2016-09-16 2017-09-15 ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
JP2022161777A Pending JP2022189853A (ja) 2016-09-16 2022-10-06 ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤
JP2024195965A Pending JP2025022910A (ja) 2016-09-16 2024-11-08 ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022161777A Pending JP2022189853A (ja) 2016-09-16 2022-10-06 ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤
JP2024195965A Pending JP2025022910A (ja) 2016-09-16 2024-11-08 ｍｅｎｉｎ－ＭＬＬ相互作用の阻害剤

Country Status (16)

Country Link
US (3) US10899758B2 (https=)
EP (2) EP4230627A3 (https=)
JP (3) JP2019529421A (https=)
KR (1) KR102536029B1 (https=)
CN (3) CN110325533B (https=)
AR (1) AR109658A1 (https=)
AU (1) AU2017326006B2 (https=)
CA (1) CA3036987A1 (https=)
DK (1) DK3512850T3 (https=)
ES (1) ES2948949T3 (https=)
FI (1) FI3512850T3 (https=)
IL (2) IL295972A (https=)
MX (2) MX2019003091A (https=)
PL (1) PL3512850T3 (https=)
TW (1) TWI757340B (https=)
WO (1) WO2018053267A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548618A (ja) * 2019-09-20 2022-11-21 ノバルティス アーゲー Ｍｌｌ１阻害剤及び抗癌剤
JP2024521879A (ja) * 2021-06-01 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
AU2017326006B2 (en) * 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
CN110248946B (zh) 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
MX2019011412A (es) 2017-03-31 2020-02-07 Univ Michigan Regents Piperidinas como inhibidores de menina covalentes.
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
US11447484B2 (en) * 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
US11325921B2 (en) 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
KR102779601B1 (ko) * 2018-08-27 2025-03-12 스미토모 파마 가부시키가이샤 광학 활성인 아자비시클로환 유도체
CA3106385A1 (en) * 2018-09-13 2020-03-19 Kissei Pharmaceutical Co., Ltd. Imidazopyridinone compound
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
JP7618567B2 (ja) * 2019-09-27 2025-01-21 住友ファーマ株式会社 架橋型光学活性２級アミン誘導体
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
EP4132932A4 (en) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
TW202200589A (zh) 2020-05-28 2022-01-01 瑞士商諾華公司 Ｍｌｌ１抑制劑及抗癌劑
EP4263535A1 (en) 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
CA3215379A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
US20240417405A1 (en) 2021-05-08 2024-12-19 Janssen Pharmaceutica Nv Substituted Spiro Derivatives
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction
JP2024521902A (ja) 2021-06-03 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
WO2022262796A1 (en) 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
US20250000799A1 (en) * 2021-11-11 2025-01-02 V-Ensure Pharma Technologies Private Limited Reconstitutable, Single Use Antidiabetic Compositions
US20250197392A1 (en) * 2022-04-08 2025-06-19 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
JP2025541695A (ja) * 2022-11-30 2025-12-23 ヤンセン ファーマシューティカ エヌ．ベー． 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体
CN120359221A (zh) * 2022-11-30 2025-07-22 詹森药业有限公司 环丁基取代的双环化合物
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
CN121969626A (zh) * 2023-09-27 2026-05-01 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用
WO2025119184A1 (zh) * 2023-12-04 2025-06-12 首药控股(北京)股份有限公司 取代的多环化合物
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
WO2026062248A1 (en) * 2024-09-20 2026-03-26 Acerta Pharma B.V. Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527359A (ja) * 1998-09-18 2002-08-27 ビーエーエスエフ アクチェンゲゼルシャフト キナーゼインヒビターとしての４−アミノピロリピリミジン
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
WO2011152351A1 (ja) * 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
JP2013529179A (ja) * 2010-03-15 2013-07-18 プロクシマゲン リミテッド 新規酵素阻害化合物
JP2014532060A (ja) * 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
JP2015537033A (ja) * 2012-11-15 2015-12-24 ファーマサイクリックス，インク． キナーゼ阻害剤としてのピロロピリミジン化合物
WO2016143896A1 (ja) * 2015-03-11 2016-09-15 国立研究開発法人理化学研究所 難治性白血病治療薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114180A1 (de) 2005-04-25 2006-11-02 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6327713B2 (ja) * 2012-07-27 2018-05-23 国立研究開発法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
US20160113893A1 (en) * 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
CA2922058A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
AU2017326006B2 (en) * 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527359A (ja) * 1998-09-18 2002-08-27 ビーエーエスエフ アクチェンゲゼルシャフト キナーゼインヒビターとしての４−アミノピロリピリミジン
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP2013529179A (ja) * 2010-03-15 2013-07-18 プロクシマゲン リミテッド 新規酵素阻害化合物
WO2011152351A1 (ja) * 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
JP2014532060A (ja) * 2011-10-03 2014-12-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 癌を治療するためのピロロピリミジン化合物
JP2015537033A (ja) * 2012-11-15 2015-12-24 ファーマサイクリックス，インク． キナーゼ阻害剤としてのピロロピリミジン化合物
WO2016143896A1 (ja) * 2015-03-11 2016-09-15 国立研究開発法人理化学研究所 難治性白血病治療薬

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022548618A (ja) * 2019-09-20 2022-11-21 ノバルティス アーゲー Ｍｌｌ１阻害剤及び抗癌剤
JP7344372B2 (ja) 2019-09-20 2023-09-13 ノバルティス アーゲー Ｍｌｌ１阻害剤及び抗癌剤
JP2024521879A (ja) * 2021-06-01 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体

Also Published As

Publication number Publication date
MX2019003091A (es) 2019-07-08
AU2017326006B2 (en) 2021-10-28
ES2948949T3 (es) 2023-09-22
TW201825486A (zh) 2018-07-16
WO2018053267A1 (en) 2018-03-22
US10899758B2 (en) 2021-01-26
US11739085B2 (en) 2023-08-29
EP3512850A1 (en) 2019-07-24
RU2019111169A3 (https=) 2020-12-30
US20240124447A1 (en) 2024-04-18
US20210179611A1 (en) 2021-06-17
JP2022189853A (ja) 2022-12-22
KR102536029B1 (ko) 2023-05-23
IL265028B (en) 2022-09-01
BR112019005030A2 (pt) 2019-06-18
EP4230627A3 (en) 2023-11-15
IL265028A (https=) 2019-04-30
MX2022013841A (es) 2022-11-30
KR20190111008A (ko) 2019-10-01
CA3036987A1 (en) 2018-03-22
CN110325533B (zh) 2025-11-04
CN121735946A (zh) 2026-03-27
EP4230627A2 (en) 2023-08-23
DK3512850T3 (da) 2023-07-03
US20190202830A1 (en) 2019-07-04
CN118359610A (zh) 2024-07-19
TWI757340B (zh) 2022-03-11
CN110325533A (zh) 2019-10-11
PL3512850T3 (pl) 2023-10-09
RU2019111169A (ru) 2020-10-20
JP2025022910A (ja) 2025-02-14
IL295972A (en) 2022-10-01
NZ751049A (en) 2025-05-02
AU2017326006A1 (en) 2019-03-21
FI3512850T3 (fi) 2023-06-20
AR109658A1 (es) 2019-01-09
EP3512850B1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
US11739085B2 (en) Inhibitors of the menin-MLL interaction
JP7461390B2 (ja) メニン－ｍｌｌ相互作用の阻害剤
JP2018538330A (ja) ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
RU2829484C2 (ru) Ингибиторы взаимодействия менин-mll
HK40098918A (en) Inhibitors of the menin-mll interaction
BR112019005030B1 (pt) Compostos, sais, formas cristalinas, composições farmacêuticas e seus usos como inibidores da interação de menin-llm
HK40012443B (en) Inhibitors of the menin-mll interaction
HK40012443A (en) Inhibitors of the menin-mll interaction
BR112018075260B1 (pt) Compostos inibidores da interação de menina-llm, composição farmacêutica, sal, forma cristalina e uso dos mesmos

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221006

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221007

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221101

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221121

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221122

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221206